MCID: AVN001
MIFTS: 50

Avian Influenza

Categories: Respiratory diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Avian Influenza

MalaCards integrated aliases for Avian Influenza:

Name: Avian Influenza 12 56 3 14
Bird Flu 12 41 3
Influenza in Birds 42 69
Avian Flu 12

Characteristics:

Orphanet epidemiological data:

56
avian influenza
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:4492
ICD10 33 J09.X
MeSH 42 D005585
SNOMED-CT 64 55604004
Orphanet 56 ORPHA454836
ICD10 via Orphanet 34 J09
UMLS 69 C0016627

Summaries for Avian Influenza

MedlinePlus : 41 birds, just like people, get the flu. bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. usually bird flu viruses only infect other birds. it is rare for people to get infected with bird flu viruses, but it can happen. two types, h5n1 and h7n9, have infected some people during outbreaks in asia, africa, the pacific, the middle east, and parts of europe. there have also been some rare cases of other types of bird flu affecting people in the united states. most of the people who get bird flu have had close contact with infected birds or with surfaces that have been contaminated by the birds' saliva, mucous, or droppings. it is also possible to get it by breathing in droplets or dust that contain the virus. rarely, the virus has spread from one person to another. it may also be possible to catch bird flu by eating poultry or eggs that are not well cooked. bird flu illness in people can range from mild to severe. often, the symptoms are similar to the seasonal flu, such as fever cough sore throat runny or stuffy nose muscle or body aches fatigue headaches eye redness (or conjunctivitis) difficulty breathing in some cases, bird flu can cause serious complications and death. as with seasonal flu, some people are at higher risk for serious illness. they include pregnant women, people with weakened immune systems, and seniors aged 65 and older. treatment with antiviral medicines may make the illness less severe. they may also help prevent the flu in people who were exposed to it. there is currently no vaccine available to the public. the government does have a supply of a vaccine for one type of h5n1 bird flu virus and could distribute it if there was an outbreak that spread easily from person to person. centers for disease control and prevention

MalaCards based summary : Avian Influenza, also known as bird flu, is related to influenza and newcastle disease, and has symptoms including coughing, fever and pruritus. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways/superpathways are Cytokine Signaling in Immune system and RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways. The drugs Vaccines and Aluminum hydroxide have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and lung, and related phenotypes are cardiovascular system and hematopoietic system

CDC : 3 Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. The links below offer more information about avian influenza.

Disease Ontology : 12 An influenza that results_in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted_by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

Wikipedia : 72 Avian influenza—known informally as avian flu or bird flu is a variety of influenza caused by viruses... more...

Related Diseases for Avian Influenza

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to Avian Influenza

Symptoms & Phenotypes for Avian Influenza

UMLS symptoms related to Avian Influenza:


coughing, fever, pruritus, snoring

MGI Mouse Phenotypes related to Avian Influenza:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CRK CXCL10 FURIN NEU1 PCSK5 PCSK6
2 hematopoietic system MP:0005397 9.91 CXCL10 DDX58 FURIN IRF7 NEU1 PCSK5
3 digestive/alimentary MP:0005381 9.87 CRK DDX58 FURIN PCSK5 PCSK6 SCRIB
4 immune system MP:0005387 9.81 SFTPD STAT2 TNF CXCL10 DDX58 FURIN
5 mortality/aging MP:0010768 9.73 CRK CXCL10 DDX58 FURIN IRF7 NEU1
6 respiratory system MP:0005388 9.17 NEU1 PCSK5 PCSK6 SCRIB SFTPD TNF

Drugs & Therapeutics for Avian Influenza

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2
Aluminum hydroxide Approved Phase 2, Phase 3,Phase 1 21645-51-2
3
Formaldehyde Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-00-0 712
4
Oseltamivir Approved Phase 2, Phase 3,Phase 1 204255-11-8, 196618-13-0 65028
5
Lactitol Investigational Phase 3,Phase 2,Phase 1 585-86-4 3871
6 Hemagglutinins Phase 3,Phase 1,Phase 2
7 MF59 oil emulsion Phase 3,Phase 2,Phase 1
8 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
9 Antibodies Phase 3,Phase 2,Phase 1
10 Immunoglobulins Phase 3,Phase 2,Phase 1
11 Agglutinins Phase 3,Phase 1,Phase 2
12 Cathartics Phase 3
13 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
14 Immunosuppressive Agents Phase 3
15 Laxatives Phase 3
16 Anti-Infective Agents Phase 2, Phase 3,Phase 1
17 Antiviral Agents Phase 2, Phase 3,Phase 1
18
Zanamivir Approved, Investigational Phase 2,Phase 1 139110-80-8 60855
19
Aluminum sulfate Approved Phase 2 10043-01-3
20
Amantadine Approved Phase 2 768-94-5 2130
21
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
22 Adjuvants, Immunologic Phase 2,Phase 1
23 Antacids Phase 1, Phase 2
24 Anti-Ulcer Agents Phase 1, Phase 2
25 gamma-Globulins Phase 2
26 Immunoglobulins, Intravenous Phase 2
27 Rho(D) Immune Globulin Phase 2
28 Analgesics Phase 2
29 Analgesics, Non-Narcotic Phase 2
30 Antiparkinson Agents Phase 2
31 Dopamine Agents Phase 2
32 Neurotransmitter Agents Phase 2
33 Peripheral Nervous System Agents Phase 2
34
Probenecid Approved Phase 1 57-66-9 4911
35
Peramivir Approved, Investigational Phase 1 229614-55-5, 330600-85-6 151164
36
Inulin Approved, Nutraceutical Phase 1 9005-80-5 24763
37 Anti-Bacterial Agents Phase 1
38 Antibiotics, Antitubercular Phase 1
39 ISCOMs Phase 1
40 Antirheumatic Agents Phase 1
41 Renal Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 216)

id Name Status NCT ID Phase Drugs
1 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
2 Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old Completed NCT01730378 Phase 4
3 The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine Completed NCT02269852 Phase 4
4 A Safety and Immunogenicity Study of IVACFLU-A/H5N1 Unknown status NCT02612909 Phase 2, Phase 3
5 H5N1 Vaccine Study in Japanese Adults Completed NCT01382329 Phase 2, Phase 3
6 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Completed NCT02839330 Phase 3
7 Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Completed NCT01310413 Phase 3
8 Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Completed NCT01788228 Phase 3
9 Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Completed NCT00434733 Phase 3
10 Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups Completed NCT00711295 Phase 3
11 Japanese Pediatric H5N1 Vaccine Study Completed NCT01911754 Phase 3
12 H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older Completed NCT01774032 Phase 3
13 Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Completed NCT00462215 Phase 3
14 Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Completed NCT00848029 Phase 3
15 Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine Completed NCT02107807 Phase 3
16 Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers Completed NCT01987011 Phase 3
17 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above Completed NCT00319098 Phase 3
18 Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years Completed NCT00616928 Phase 3
19 Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects Completed NCT00841763 Phase 3
20 A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children Completed NCT01379937 Phase 3
21 A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine. Completed NCT00812981 Phase 3
22 Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions Completed NCT02091908 Phase 3
23 Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules Completed NCT00652743 Phase 3
24 Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases Completed NCT00519064 Phase 3
25 Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One Withdrawn NCT01546935 Phase 2, Phase 3 Oseltamivir
26 Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses Unknown status NCT00417560 Phase 1, Phase 2
27 Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults Unknown status NCT01640691 Phase 1, Phase 2
28 Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Unknown status NCT02095444 Phase 1, Phase 2 Menstrual blood stem cells
29 Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine Completed NCT00561184 Phase 2
30 H7N9 Mix and Match With MF59 in Healthy Elderly Persons Completed NCT02213354 Phase 2 MF59
31 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines Completed NCT00478816 Phase 2
32 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults Completed NCT01776541 Phase 2
33 Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years Completed NCT00537524 Phase 2
34 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects Completed NCT01766921 Phase 2
35 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) Completed NCT01910519 Phase 2
36 Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Completed NCT00914771 Phase 2
37 H5N1 (Clade 2) Vaccination of Adults and Elderly Completed NCT00680069 Phase 1, Phase 2
38 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children Completed NCT01776554 Phase 2
39 Inactivated Influenza A/H5N1 Vaccine in the Elderly Completed NCT00230750 Phase 1, Phase 2 Placebo
40 Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults Completed NCT01195038 Phase 2
41 A/H5N1 Vaccine in Healthy Children Aged 2-9 Years Completed NCT00133536 Phase 1, Phase 2 Placebo
42 H7N9 Boost in Healthy Adults Completed NCT02586792 Phase 2
43 Safety, Reactogenicity and Immunogenicity of an H5N1 VLP Completed NCT00519389 Phase 1, Phase 2
44 A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64 Completed NCT00695669 Phase 2
45 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Completed NCT00298233 Phase 2 Oseltamivir
46 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults Completed NCT01416571 Phase 2
47 H7N9 Mix and Match With MF59 in Healthy Adults Completed NCT01938742 Phase 2 MF59
48 A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant Completed NCT02078674 Phase 1, Phase 2
49 H7N9 Mix and Match With AS03 and MF59 in Healthy Adults Completed NCT01942265 Phase 2 AS03;MF59
50 Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults Completed NCT00382187 Phase 2

Search NIH Clinical Center for Avian Influenza

Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

Anatomical Context for Avian Influenza

MalaCards organs/tissues related to Avian Influenza:

39
Eye, Testes, Lung, T Cells, B Cells, Trachea, Myeloid

Publications for Avian Influenza

Articles related to Avian Influenza:

(show top 50) (show all 732)
id Title Authors Year
1
H9N2 avian influenza virus enhances the immune responses of BMDCs by down-regulating miR29c. ( 28063705 )
2017
2
Transmission and immunopathology of the avian influenza virus A/Anhui/1/2013 (H7N9) human isolate in three commonly commercialized avian species. ( 28905526 )
2017
3
Novel reassortant clade 2.3.4.4 avian influenza A (H5N8) virus in a grey heron in South Korea in 2017. ( 28900762 )
2017
4
Risk of Human Infections With Highly Pathogenic H5N2 and Low Pathogenic H7N1 Avian Influenza Strains During Outbreaks in Ostriches in South Africa. ( 28934458 )
2017
5
Pathogenesis, Transmissibility, and Tropism of a Highly Pathogenic Avian Influenza A(H7N7) Virus Associated With Human Conjunctivitis in Italy, 2013. ( 28934452 )
2017
6
Single PA mutation as a high yield determinant of avian influenza vaccines. ( 28084423 )
2017
7
Estimating Risks of Inapparent Avian Exposure for Human Infection: Avian Influenza Virus A (H7N9) in Zhejiang Province, China. ( 28054599 )
2017
8
Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. ( 28079520 )
2017
9
Five distinct reassortants of H5N6 highly pathogenic avian influenza A viruses affected Japan during the winter of 2016-2017. ( 28892736 )
2017
10
EVALUATION OF A COMMERCIAL COMPETITIVE ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF AVIAN INFLUENZA VIRUS SUBTYPE H5 ANTIBODIES IN ZOO BIRDS. ( 28920801 )
2017
11
Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy. ( 28077631 )
2017
12
Clusters of Human Infections With Avian Influenza A(H7N9) Virus in China, March 2013 to June 2015. ( 28934462 )
2017
13
OIE avian influenza portal. ( 28062760 )
2017
14
Novel variants of clade 2.3.2.1 H5N1 highly pathogenic avian influenza virus in migratory waterfowl of Hongze Lake. ( 28062014 )
2017
15
Genome Sequence of an H9N2 Avian Influenza Virus Strain with Hemagglutinin-Neuraminidase Combination, Isolated from a Quail in Guangxi, Southern China. ( 28935735 )
2017
16
Current situation of H9N2 subtype avian influenza in China. ( 28915920 )
2017
17
Infectious dose-dependent accumulation of live highly pathogenic avian influenza H5N1 virus in chicken skeletal muscle-implications for public health. ( 28941132 )
2017
18
Quantifying predictors for the spatial diffusion of avian influenza virus in China. ( 28086751 )
2017
19
Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. ( 28889970 )
2017
20
Novel real-time PCR-based patho- and phylotyping of potentially zoonotic avian influenza A subtype H5 viruses at risk of incursion into Europe in 2017. ( 28084214 )
2017
21
New real time and conventional RT-PCRs for updated molecular diagnosis of infectious bronchitis virus infection (IBV) in chickens in Egypt associated with frequent co-infections with avian influenza and Newcastle Disease viruses. ( 28336367 )
2017
22
Experimental infection of mandarin duck with highly pathogenic avian influenza A (H5N8 and H5N1) viruses. ( 28062008 )
2017
23
Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models. ( 28061848 )
2017
24
Natural reassortants between potentially zoonotic avian influenza viruses H5N1 and H9N2 from Egypt display distinct pathogenic phenotypes in experimentally infected chickens and ferrets. ( 28931674 )
2017
25
Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus. ( 28895870 )
2017
26
Thermal Inactivation of avian influenza virus in poultry litter as a method to decontaminate poultry houses. ( 28903878 )
2017
27
Proteome Response of Chicken Embryo Fibroblast Cells to Recombinant H5N1 Avian Influenza Viruses with Different Neuraminidase Stalk Lengths. ( 28079188 )
2017
28
Efficacy of recombinant measles virus expressing highly pathogenic avian influenza virus (HPAIV) antigen against HPAIV infection in monkeys. ( 28931922 )
2017
29
Mild Respiratory Illness Among Young Children Caused by Highly Pathogenic Avian Influenza A (H5N1) Virus Infection in Dhaka, Bangladesh, 2011. ( 28934459 )
2017
30
Annexin A2 (ANXA2) interacts with nonstructural protein 1 and promotes the replication of highly pathogenic H5N1 avian influenza virus. ( 28893180 )
2017
31
Highly Pathogenic Avian Influenza A(H5N1) Viruses at the Animal-Human Interface in Vietnam, 2003-2010. ( 28934457 )
2017
32
Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus. ( 27640441 )
2016
33
Isolation and phylogenetic characterization of haemagglutinin and neuraminidase genes of H9N2 low pathogenicity avian influenza virus isolated from commercial layers in India. ( 28004018 )
2016
34
The avian influenza H9N2 at avian-human interface: A possible risk for the future pandemics. ( 28083072 )
2016
35
Ecosystem Interactions Underlie the Spread of Avian Influenza A Viruses with Pandemic Potential. ( 27166585 )
2016
36
Predicting Avian Influenza Co-Infection with H5N1 and H9N2 in Northern Egypt. ( 27608035 )
2016
37
Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation. ( 28012921 )
2016
38
Avian influenza Prevention Zone declared. ( 27932709 )
2016
39
Genetic characterization and phylogenic analysis of H5N1 avian influenza virus detected in peafowl in Kirkuk province, Iraq. ( 28036106 )
2016
40
Pre-immune state induced by chicken interferon gamma inhibits the replication of H1N1 human and H9N2 avian influenza viruses in chicken embryo fibroblasts. ( 27121613 )
2016
41
Corrigendum: Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. ( 27648005 )
2016
42
Avian Influenza Virus H5 Strain with North American and Eurasian Lineage Genes in an Antarctic Penguin. ( 27662612 )
2016
43
Unexpected Inter-farm Transmission Dynamics During a Highly Pathogenic Avian Influenza Epidemic. ( 27147741 )
2016
44
Genetic diversity and pathogenic potential of low pathogenic H7 avian influenza viruses isolated from wild migratory birds in Korea. ( 27615552 )
2016
45
Novel Avian Influenza A(H5N8) Viruses in Migratory Birds, China, 2013-2014. ( 27192098 )
2016
46
Isolation of H5N6, H7N9 and H9N2 avian influenza A viruses from air sampled at live poultry markets in China, 2014 and 2015. ( 27608369 )
2016
47
The Dynamics of Avian Influenza: Individual-Based Model with Intervention Strategies in Traditional Trade Networks in Phitsanulok Province, Thailand. ( 27110273 )
2016
48
Characterization and Sequencing of an H6N6 Avian Influenza Virus Isolated from Sansui Sheldrake Ducks in Guizhou, Southwestern China. ( 27174267 )
2016
49
Interventions in live poultry markets for the control of avian influenza: a systematic review. ( 27213177 )
2016
50
Characteristics of two highly pathogenic avian influenza H5N8 viruses with different pathogenicity in mice. ( 27589977 )
2016

Variations for Avian Influenza

Expression for Avian Influenza

Search GEO for disease gene expression data for Avian Influenza.

Pathways for Avian Influenza

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 CRK CXCL10 DDX58 IRF7 STAT2 TNF
2
Show member pathways
12.38 CXCL10 DDX58 IRF7 TNF
3
Show member pathways
12.19 CXCL10 DDX58 FURIN IRF7 STAT2 TMPRSS13
4 12.15 CXCL10 DDX58 IRF7 STAT2 TNF
5
Show member pathways
11.85 CXCL10 SFTPD TNF
6
Show member pathways
11.75 IRF7 STAT2 TNF
7 11.74 DDX58 IRF7 STAT2 TNF
8
Show member pathways
10.69 DDX58 IRF7 STAT2
9
Show member pathways
9.5 FURIN PCSK5 PCSK6

GO Terms for Avian Influenza

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CXCL10 FURIN NEU1 PCSK5 PCSK6 SFTPD
2 Golgi lumen GO:0005796 8.8 FURIN PCSK5 PCSK6

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.93 FURIN PCSK5 PCSK6 TMPRSS11A TMPRSS13
2 viral process GO:0016032 9.88 DDX58 IRF7 SCRIB STAT2
3 defense response to virus GO:0051607 9.71 CXCL10 DDX58 IRF7 STAT2
4 response to virus GO:0009615 9.62 CXCL10 DDX58 IRF7 TNF
5 protein processing GO:0016485 9.61 FURIN PCSK5 PCSK6
6 positive regulation of interleukin-8 production GO:0032757 9.57 DDX58 TNF
7 positive regulation of interferon-beta production GO:0032728 9.56 DDX58 IRF7
8 negative regulation of myoblast differentiation GO:0045662 9.55 CXCL10 TNF
9 signal peptide processing GO:0006465 9.52 FURIN PCSK5
10 embryonic digestive tract development GO:0048566 9.51 PCSK5 TNF
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.49 FURIN TNF
12 positive regulation of interferon-alpha production GO:0032727 9.48 DDX58 IRF7
13 secretion by cell GO:0032940 9.46 FURIN PCSK6
14 peptide biosynthetic process GO:0043043 9.37 FURIN PCSK5
15 peptide hormone processing GO:0016486 9.33 FURIN PCSK5 PCSK6
16 nerve growth factor production GO:0032902 9.26 FURIN PCSK6
17 regulation of lipoprotein lipase activity GO:0051004 9.13 FURIN PCSK5 PCSK6
18 nerve growth factor processing GO:0032455 8.8 FURIN PCSK5 PCSK6

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.91 DDX58 FURIN NEU1 PCSK5 PCSK6 TMPRSS11A
2 peptidase activity GO:0008233 9.65 FURIN PCSK5 PCSK6 TMPRSS11A TMPRSS13
3 endopeptidase activity GO:0004175 9.5 FURIN PCSK5 PCSK6
4 serine-type endopeptidase activity GO:0004252 9.35 FURIN PCSK5 PCSK6 TMPRSS11A TMPRSS13
5 nerve growth factor binding GO:0048406 9.16 FURIN PCSK6
6 serine-type peptidase activity GO:0008236 9.02 FURIN PCSK5 PCSK6 TMPRSS11A TMPRSS13

Sources for Avian Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....